Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Completed
Stemcentrx
Phase 1/Phase 2
The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine
(SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has
progressed or recurred following standard chemotherapy. Once a safe and tolerable dose is
determined, the anti-cancer activity of SC16LD6.5 will be assessed by measuring the extent of
tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a
protein that appears to be expressed on the surface of most small cell lung cancers that have
been assessed using an immunohistochemical assay. The drug, D6.5, is a very potent form of
chemotherapy, specifically a DNA-damaging agent, that is cell cycle independent. ADC's
theoretically provide more precise delivery of chemotherapy to cancer cells, possibly
improving effectiveness relative to toxicities.
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Completed
AbbVie
Phase 2
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a
third-line and later treatment for participants with relapsed or refractory delta-like
protein 3 (DLL3) expressing small cell lung cancer (SCLC).
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Completed
Stemcentrx
Phase 2
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a
third-line and later treatment for participants with relapsed or refractory delta-like
protein 3 (DLL3) expressing small cell lung cancer (SCLC).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
